Search Results

VITROS Immunodiagnostics NT-proBNP Reagent Pack: For the in vitro quantitative measurement of N-terminal pro Brain Natriuretic Peptide (NT-proBNP) in human serum and plasma (EDTA or heparin) to aid in the diagnosis of congestive heart failure and for the risk stratification of acute coronary syndrome and congestive heart failure. The test is further indicated as an aid in the assessment of increased risk of cardiovascular events and mortality in patients at risk for heart failure who have stable coronary artery disease. The test can also be used in the assessment of heart failure severity in patients diagnosed with congestive heart failure.

VITROS Immunodiagnostic Products NT-proBNP Calibrator For in vitro use in the calibration of the VITROS Immunodiagnostic System for the quantitative measurement of N-terminal pro Brain Natriuretic Peptide (NT-proBNP) in human serum and plasma (EDTA or heparin).

VITROS Immunodiagnostic Products NT-proBNP Range Verifiers For the in vitro use in verifying the calibration range of the VITROS Immunodiagnostic System when used for the quantitative measurement of N-terminal pro Brain Natriuretic Peptide (NT-proBNP).

The VITROS Immunodiagnostic System uses luminescence as the signal in the quantitative and semi-quantitative determination of selected analytes in human body fluids, commonly serum and plasma. Coated microwells are used as the solid phase separation system. The system is comprised of there main elements: The VITROS Immunodiagnostic Products range of immunoassay products in this case the VITROS Immunodiagnostic Products NTproBNP Reagent Pack, the VITROS Immunodiagnostic Products NT-proBNP Calibrators, and the VITROS Immunodiagnostic Products NT-proBNP Range Verifiers (which are combined by the VITROS Immunodiagnostic system to perform the VITROS NTproBNP assay) and VITROS Immunodiagnostic Products High Sample Diluent B. The VITROS Immunodiagnostic System -- instrumentation, which provides automated use of the immunoassay kits. Common reagents used by the VITROS System in each assay.

The provided document is a 510(k) summary for the VITROS Immunodiagnostic Products NT-proBNP Reagent Pack, Calibrator, and Range Verifier. This type of regulatory submission focuses on demonstrating substantial equivalence to a predicate device rather than providing detailed acceptance criteria and study results for novel device performance.

Therefore, the document does not contain the specific information requested regarding acceptance criteria and a study proving the device meets those criteria in the typical format of a clinical performance study for an AI-powered device. Instead, it relies on demonstrating comparable performance to an already cleared predicate device.

Here's a breakdown of why the requested information cannot be fully provided from this document:

• No explicit acceptance criteria or performance study for device novelty: Since this is a substantial equivalence submission for an in vitro diagnostic (IVD) device, the "acceptance criteria" are implicitly met by demonstrating that the new device's performance characteristics (e.g., measuring range, analytical sensitivity, functional sensitivity, intended use) are substantially equivalent to a legally marketed predicate device. There isn't an independent study outlined to "prove" the device meets specific (novel) acceptance criteria, but rather a comparison to an established device.
• No AI component: This device is an immunoassay system for measuring NT-proBNP, not an AI-powered diagnostic tool. Therefore, questions related to AI-specific elements (like test sets, training sets, adjudication, MRMC studies, or standalone algorithm performance) are not applicable.

Despite these limitations, I can extract and infer some information based on the comparison tables provided.

Inferred Acceptance Criteria and Reported Device Performance (Based on Predicate Device Comparison)

The acceptance criteria for this device are implicitly tied to demonstrating performance comparable to the predicate device (Roche Elecsys proBNP Immunoassay K051382 for the Reagent Pack and Calibrator, and VITROS Immunodiagnostic Products CEA Range Verifiers K990984 for the Range Verifiers).

Regarding the specific questions:

1. A table of acceptance criteria and the reported device performance:

   • See the table above. These are inferred acceptance criteria based on the characteristics of the predicate device that the new device aims to be equivalent to. The "reported device performance" is the claim made by the new device.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective):

   • This information is not provided in a 510(k) summary for an IVD device of this type. The summary focuses on comparing technical and performance characteristics, not on a detailed clinical study with a "test set" in the context of an AI device.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience):

   • Not applicable, as this is an immunoassay, not an AI device requiring expert ground truth in this manner.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

   • Not applicable, as this is an immunoassay, not an AI device using adjudication methods for a test set.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • Not applicable, as this is an immunoassay, not an AI device involving human readers or MRMC studies.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

   • Not applicable, as this is an immunoassay, not an AI algorithm. The device functions as a standalone quantitative measurement system.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc):

   • For an immunoassay, "ground truth" typically refers to established analytical reference methods or reference materials. The document implies that the "truth" for the new device's measurements is established by its demonstrated correlation or equivalence to the predicate device's measurements, which are already accepted. For calibrators, the "levels" are specific pg/mL concentrations (e.g., Cal 1 0 pg/mL, Cal 2 150 pg/mL).

8. The sample size for the training set:

   • Not applicable, as this is an immunoassay. The concept of a "training set" is relevant for machine learning algorithms, which are not involved here. Assay development involves method optimization and validation, not model training.

9. How the ground truth for the training set was established:

   • Not applicable, as there is no "training set" in the AI sense for this immunoassay.

Ask a specific question about this device